RecruitingNCT06804135

Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer

Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer (STIRR Cervix Study)

Sponsor

Tata Memorial Hospital

Enrollment

110 participants

Start Date

Oct 25, 2025

Study Type

OBSERVATIONAL

Conditions

Cervical Carcinoma

Summary

Radiotherapy result in tumor cell death by creating an immune potentiation effect, but can also lead to long lasting immune suppression. Thus the investigators hypothesize that pelvic and/or para-aortic radiotherapy for cervical cancer affects local tumor immunity as well as systemic immune response that may be instrumental for long term cancer cure. The goal of this observational study is to understand the effect of various radiotherapy dose per fraction, total dose and field volumes of radiation on systemic and tumor immune response in cervical cancer. The outcome of the study would be useful in improving the quality of radiation treatment and in reducing disease recurrence and improving survival in patients with cervical cancer.

Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria14

Age 18 years and above.
Ability to tolerate full course of pelvic radiotherapy+/- chemotherapy +/- brachytherapy.
Ability to understand and willingness to sign an informed consent document.
Should be willing to undergo extra biopsies and blood samples collection for translational research study.
Cohort A:
Patients diagnosed with LACC Stage IB2 - IIIC1, as per FIGO 2018 Classification for Radical Cohort.
Stage IIIB-IVA where palliative RT is indicated for palliative cohort.
No previous irradiation to the pelvis or chemo therapy.
Cohort B:
Patients diagnosed with LACC Stage IIIC2, as per FIGO 2018 Classification.
No previous irradiation to the pelvis or chemotherapy.
Cohort C:
Patients diagnosed with gynecological cancer and presenting with need of infield radiation.
Planned for reirradiation.